200 kHz 肿瘤治疗场 (TTFields) 已获得临床批准用于新诊断的胶质母细胞瘤 (nGBM)。由于其对传统监测 MRI 脑部扫描的影响是模棱两可的，因此我们研究了其对灌注 MRI (pMRI) 脑部扫描的影响。每位患者均接受机构标准 pMRI：动态对比增强 (DCE) 和动态磁敏感对比 (DSC) pMRI 三次要点：基线、2 个月和 6 个月辅助治疗。在每个时间点，评估 T1 前与对比后肿瘤体积 (ΔT1) 之间的差异以及这些 pMRI 指标：归一化和标准化相对脑血容量 (nRCBV、sRCBV)；血浆体积分数 (Vp)、每单位组织体积的血管外细胞外空间 (EES) 体积 (Ve)、血脑屏障 (BBB) 渗透性 (Ktrans) 以及钆从 EES 回流到血管系统的时间常数 (Kep) ）。使用秩和分析进行组间比较，并通过自举法评估结果的可能再现性。在 13 个 pMRI 数据集（11 个 nGBM，2 个复发性 GBM）中，疗法包括仅替莫唑胺 (n = 9) 和替莫唑胺 TTFields (n = 4).患者或肿瘤特征没有发现显着差异。与仅使用替莫唑胺相比，替莫唑胺 TTFields 并未显着影响 pMRI 指标从基线到 2 个月的百分比变化。但在 2 至 6 个月期间，替莫唑胺 TTFields 显着增加了 nRCBV（26.9% [四分位距 55.1%] 与 -39.1% [37.0%]，p = 0.049）、sRCBV（9.5% [39.7]）的百分比变化%] vs -30.5% [39.4%]，p = 0.049)，Ktrans ( 54.6% [1768.4%] vs -26.9% [61.2%]，p = 0.024)，Ve ( 111.0% [518.1%] vs -13.0% [22.5%]，p = 0.048）和 Vp（98.8% [2172.4%] vs -24.6% [53.3%]，p = 0.024）与仅使用替莫唑胺相比。使用 pMRI，我们提供了预-关于 TTFields 对 GBM 肿瘤血容量和 BBB 通透性影响的临床研究。

200 kHz tumor treating fields (TTFields) is clinically approved for newly-diagnosed glioblastoma (nGBM). Because its effects on conventional surveillance MRI brain scans are equivocal, we investigated its effects on perfusion MRI (pMRI) brain scans.Each patient underwent institutional standard pMRI: dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) pMRI at three time points: baseline, 2-, and 6-months on-adjuvant therapy. At each timepoint, the difference between T1 pre- versus post-contrast tumor volume (ΔT1) and these pMRI metrics were evaluated: normalized and standardized relative cerebral blood volume (nRCBV, sRCBV); fractional plasma volume (Vp), volume of extravascular extracellular space (EES) per volume of tissue (Ve), blood-brain barrier (BBB) permeability (Ktrans), and time constant for gadolinium reflux from EES back into the vascular system (Kep). Between-group comparisons were performed using rank-sum analysis, and bootstrapping evaluated likely reproducibility of the results.Among 13 pMRI datasets (11 nGBM, 2 recurrent GBM), therapies included temozolomide-only (n = 9) and temozolomide + TTFields (n = 4). No significant differences were found in patient or tumor characteristics. Compared to temozolomide-only, temozolomide + TTFields did not significantly affect the percent-change in pMRI metrics from baseline to 2 months. But during the 2- to 6-month period, temozolomide + TTFields significantly increased the percent-change in nRCBV (+26.9% [interquartile range 55.1%] vs -39.1% [37.0%], p = 0.049), sRCBV (+9.5% [39.7%] vs -30.5% [39.4%], p = 0.049), Ktrans (+54.6% [1768.4%] vs -26.9% [61.2%], p = 0.024), Ve (+111.0% [518.1%] vs -13.0% [22.5%], p = 0.048), and Vp (+98.8% [2172.4%] vs -24.6% [53.3%], p = 0.024) compared to temozolomide-only.Using pMRI, we provide initial in-human validation of pre-clinical studies regarding the effects of TTFields on tumor blood volume and BBB permeability in GBM.